Please login to the form below

Greener healthcare - a shared challenge

At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.

This November, Glasgow will host the international COP26 UN climate summit. UK Government has a strong ambition to use its Presidency to drive global commitment to net zero targets. Pressure is on companies of all sectors and sizes to join Race to Zero, the campaign to rally support from global businesses, cities, and investors for a healthy, resilient, zero-carbon recovery. The green economy is fundamental within the UK narrative of Build Back Better – and the economic and social benefits of decarbonised and more efficient healthcare systems are critical to this.

The interaction between health and climate change is well documented – the World Health Organization (WHO) predicts that it will have an “overwhelmingly negative” impact on the world’s health. [1] The last year also served as a sharp reminder that climate and health inequalities often go hand in hand. More than 50 million people were hit by both climate-related disasters (floods, droughts and storms) and the COVID-19 pandemic, resulting in worsened food insecurity and compounding risk to evacuation and relief operations.[2]

At present, many solutions to climate impacts on health have an emissions cost. Analysis has suggested that combined CO2 emissions from hospitals, health services and medical supply chains across the OECD group of market economies plus China and India comprise 4% of total global emissions footprint – greater than aviation or shipping. In England alone, the NHS footprint equated to 5.4% of the country’s carbon emissions for 2019.[3]

For the wider healthcare system, opportunities for change lie in areas such as building efficiency and waste reduction – where potentially recyclable high-quality waste products in operating theatres are largely labelled as infectious clinical waste and incinerated at high financial and environmental cost.

Hospitals have also been exploring retrofitting heat recovery technology to dialysis machines, and switching operating room anaesthetics (which account for almost a third of the UK’s health and social care sector emissions) to less-polluting gas. In England there are also plans for delivery of London’s first prototype hydrogen fuel cell ambulance later this year, in addition to rollout of electric ambulances in other regions. Meanwhile the introduction of a new Chief Sustainability Officer’s Clinical Fellow Scheme aims to  embed green innovation from within the system.

This NHS momentum is underpinned by ambition to reach net zero for its direct emissions by 2040 set in October 2020, making it the first healthcare system in the world to set a net zero target. Accompanying this is a net zero target for supply chains (NHS Carbon Footprint Plus) by 2045 – with an 80% reduction pathway for 2036-39. This will encompass everything from medical devices, medicines, and manufacturing (including chemicals and gases).

The message from the Greener NHS report is clear: suppliers must meet or exceed their commitment on net zero emissions before the end of the decade. The potential for this thinking to permeate into other markets is strong – particularly with the Green Deal driving thinking across the EU –and could have wide ranging implications for access criteria for new medical devices and medicines.

Strong cross-industry effort will be needed. In 2015 the global pharmaceutical industry produced 55% more CO2 than the automotive industry.[4] A huge amount of work has been undertaken since then to decarbonise manufacturing and product design – from reusable, propellant-free inhalers to exploration of biotechnology in medicine production processes. Yet so much of the pharmaceutical sector’s ability to deliver rests upon driving change in its own wider supply chains.

Three core approaches will help support this shift:

  1. Pharmaceutical companies taking still greater responsibility for their own suppliers via procurement processes - upping renewable energy, pressing greater reduction of water consumption, or facilitating circular economy thinking on plastics.
  2. Holding governments to account around supporting longer-term infrastructure: for example, hydrogen for powering manufacturing plants and forgreen steel for healthcare products.
  3. Ensuring health system innovation is future-proofed: such as tackling the data centre emissions challenge of digital health.

There are many reasons to be optimistic about meeting the ambitious targets. Trends have shown that focused efforts can deliver on decarbonisation, while crucially maintaining economic growth and expansion of service. In the NHS emissions from health and social care were cut by 18.5% between 2007 and 2017, despite clinical activity rising by over a quarter over the same period. [5]

While the climate challenge may be international, the reputational risk for companies is much more local. There is an increasing imperative for companies to forge a UK corporate story on net zero and to adopt initiatives that show clear action at a market level, rather than just within global teams. Working on low carbon energy within government, I have seen first-hand that seismic shifts in decarbonisation occur when industry holds suppliers to account and partner with wider sectors. Now is the time for the pharmaceutical industry to take its place in vocal leadership to green its future and communicate to the NHS and others that it is part of the solution.

[1] (2019). Climate change and health. [Accessed 5 May 2021].

[2] IFRC World Disasters Report 2020 (Accessed 5 May 2021)

[3] Figure 2 from: NHS England and NHS Improvement. Delivering a Net Zero National Health Service. 2020. (accessed 1 May 2021]

[4] International comparison of health care carbon footprints: Peter-Paul Pichler, Ingram S Jaccard, Ulli Weisz and Helga Weisz, Published 24 May 2019 (Accessed  4 May 2021)

[5] NHS Long Term Plan (Accessed 4 May 2021)

18th May 2021


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications